NYSE:CLDI Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis $0.73 -0.04 (-5.43%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$0.64 -0.09 (-11.78%) As of 07/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Calidi Biotherapeutics Stock (NYSE:CLDI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Calidi Biotherapeutics alerts:Sign Up Key Stats Today's Range$0.68▼$0.7450-Day Range$0.22▼$1.0052-Week Range$0.20▼$3.89Volume2.59 million shsAverage Volume6.96 million shsMarket Capitalization$26.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California. Read More Calidi Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreCLDI MarketRank™: Calidi Biotherapeutics scored higher than 11% of companies evaluated by MarketBeat, and ranked 902nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Calidi Biotherapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Calidi Biotherapeutics are expected to grow in the coming year, from ($4.48) to ($0.88) per share. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.78% of the float of Calidi Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverCalidi Biotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calidi Biotherapeutics has recently increased by 232.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCalidi Biotherapeutics does not currently pay a dividend.Dividend GrowthCalidi Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.78% of the float of Calidi Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverCalidi Biotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calidi Biotherapeutics has recently increased by 232.79%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment0.06 News SentimentCalidi Biotherapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Calidi Biotherapeutics this week, compared to 1 article on an average week.Search Interest20 people have searched for CLDI on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows1 people have added Calidi Biotherapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Calidi Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Calidi Biotherapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.53% of the stock of Calidi Biotherapeutics is held by institutions.Read more about Calidi Biotherapeutics' insider trading history. Receive CLDI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calidi Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDI Stock News HeadlinesCalidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025July 25 at 4:45 PM | globenewswire.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24July 22, 2025 | finance.yahoo.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. July 26 at 2:00 AM | Crypto 101 Media (Ad)Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24July 22, 2025 | globenewswire.comCalidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million ...July 11, 2025 | morningstar.comMCalidi Biotherapeutics secures $4.6 million through warrant exerciseJuly 11, 2025 | investing.comCalidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer TreatmentJuly 10, 2025 | globenewswire.comCalidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross ProceedsJuly 9, 2025 | globenewswire.comSee More Headlines CLDI Stock Analysis - Frequently Asked Questions How have CLDI shares performed this year? Calidi Biotherapeutics' stock was trading at $1.15 at the beginning of 2025. Since then, CLDI shares have decreased by 36.5% and is now trading at $0.73. How were Calidi Biotherapeutics' earnings last quarter? Calidi Biotherapeutics, Inc. (NYSE:CLDI) issued its earnings results on Tuesday, November, 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.20. When did Calidi Biotherapeutics' stock split? Shares of Calidi Biotherapeutics reverse split before market open on Monday, July 15th 2024.The 1-10 reverse split was announced on Monday, July 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Calidi Biotherapeutics? Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calidi Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calidi Biotherapeutics investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Avino Silver & Gold Mines (ASM), Carlyle Secured Lending (CGBD), Devon Energy (DVN), Hercules Capital (HTGC) and Main Street Capital (MAIN). Company Calendar Last Earnings11/12/2024Today7/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:CLDI Previous SymbolNYSE:CLDI CIK1855485 Webcalidibio.com Phone858-794-9600FaxN/AEmployees38Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.22 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-344.45% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.32) per share Price / Book-0.31Miscellaneous Outstanding Shares36,321,000Free Float20,039,000Market Cap$26.51 million OptionableN/A Beta0.94 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NYSE:CLDI) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.